Harvard Bioscience (HBIO) director buys 21,000 shares on open market

Rhea-AI Filing Summary

Harvard Bioscience director William Snider reported open-market purchases of company stock. On March 16, 2026, he bought 12,525 shares of common stock at a weighted average price of $4.99 per share, with actual trade prices ranging from $4.80 to $4.95. On March 17, 2026, he bought an additional 8,475 shares at a weighted average price of $4.85, with individual trades between $4.85 and $5.00. Following these transactions, he directly holds 32,000 shares of common stock, plus 11,000 restricted stock units that fully vest on December 17, 2026. The filing notes a 10-for-1 reverse stock split of Harvard Bioscience common stock on March 13, 2026, which reduced the previously reported 110,000 restricted stock units to 11,000.

Insider Trade Summary

Net Buyer: 21,000 shares ($103,604)

Net Buy 2 txns

Insider Snider William

Role Director

Bought 21,000 shs ($104K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	8,475	$4.85	$41K
Purchase	Common Stock	12,525	$4.99	$62K

Holdings After Transaction: Common Stock — 32,000 shares (Direct)

Footnotes (1)

1. The price in Column 4 is a weighted average price. These shares were purchased in multiple transactions, and the prices actually paid ranged from $4.85 to $5.00, inclusive. The reporting person has provided to the Issuer, and will provide to any security holder of the Issuer, or the Securities and Exchange Commission ("SEC") staff, upon request, information regarding the number of shares purchased at each price within the range for all transactions reported in this Form 4 utilizing an average weighted price. The price in Column 4 is a weighted average price. These shares were purchased in multiple transactions, and the prices actually paid ranged from $4.80 to $4.95, inclusive. The reporting person has provided to the Issuer, and will provide to any security holder of the Issuer, or the SEC staff, upon request, information regarding the number of shares purchased at each price within the range for all transactions reported in this Form 4 utilizing an average weighted price. Includes (a) 12,525 shares of common stock purchased on March 16, 2026, and (b) 11,000 restricted stock units that fully vest on December 17, 2026. Includes (a) 12,525 shares of common stock purchased on March 16, 2026, (b) 8,475 shares of common stock purchased on March 17, 2026, and (c) 11,000 restricted stock units that fully vest on December 17, 2026. On March 13, 2026, the common stock of Harvard Bioscience, Inc. underwent a reverse stock split in a ratio of 10-for-1. The 11,000 restricted stock units referenced in Footnotes 3(b) and 4(c) were previously reported as covering 110,000 restricted stock units. These numbers have been adjusted to reflect the stock split that occurred on March 13, 2026.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Snider William

(Last) (First) (Middle)

C/O HARVARD BIOSCIENCE, INC.

84 OCTOBER HILL ROAD

(Street)

HOLLISTON MASSACHUSETTS 01746

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
HARVARD BIOSCIENCE INC [ HBIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/16/2026		P		12,525	A	$4.99(1)	23,525(3)(5)	D
Common Stock	03/17/2026		P		8,475	A	$4.85(2)	32,000(4)(5)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price in Column 4 is a weighted average price. These shares were purchased in multiple transactions, and the prices actually paid ranged from $4.85 to $5.00, inclusive. The reporting person has provided to the Issuer, and will provide to any security holder of the Issuer, or the Securities and Exchange Commission ("SEC") staff, upon request, information regarding the number of shares purchased at each price within the range for all transactions reported in this Form 4 utilizing an average weighted price.

2. The price in Column 4 is a weighted average price. These shares were purchased in multiple transactions, and the prices actually paid ranged from $4.80 to $4.95, inclusive. The reporting person has provided to the Issuer, and will provide to any security holder of the Issuer, or the SEC staff, upon request, information regarding the number of shares purchased at each price within the range for all transactions reported in this Form 4 utilizing an average weighted price.

3. Includes (a) 12,525 shares of common stock purchased on March 16, 2026, and (b) 11,000 restricted stock units that fully vest on December 17, 2026.

4. Includes (a) 12,525 shares of common stock purchased on March 16, 2026, (b) 8,475 shares of common stock purchased on March 17, 2026, and (c) 11,000 restricted stock units that fully vest on December 17, 2026.

5. On March 13, 2026, the common stock of Harvard Bioscience, Inc. underwent a reverse stock split in a ratio of 10-for-1. The 11,000 restricted stock units referenced in Footnotes 3(b) and 4(c) were previously reported as covering 110,000 restricted stock units. These numbers have been adjusted to reflect the stock split that occurred on March 13, 2026.

	/s/ William Snider	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did HBIO director William Snider report?

Director William Snider reported two open-market purchases of Harvard Bioscience common stock, totaling 21,000 shares on March 16 and 17, 2026. These purchases increased his direct holdings to 32,000 shares, plus 11,000 restricted stock units scheduled to vest later.

How many Harvard Bioscience (HBIO) shares did William Snider buy and at what prices?

William Snider bought 12,525 shares at a weighted average of $4.99 and 8,475 shares at a weighted average of $4.85. Actual trade prices ranged from $4.80–$4.95 and $4.85–$5.00, respectively, across multiple transactions each day.

What are William Snider’s holdings in Harvard Bioscience after these Form 4 trades?

After the reported trades, William Snider directly owns 32,000 shares of Harvard Bioscience common stock. He also holds 11,000 restricted stock units that are scheduled to fully vest on December 17, 2026, adding to his potential future equity stake.

How did the March 2026 reverse stock split affect HBIO restricted stock units?

On March 13, 2026, Harvard Bioscience completed a 10-for-1 reverse stock split. As a result, the restricted stock units tied to this filing were adjusted from 110,000 previously reported units to 11,000 units, maintaining the same economic interest post-split.

Were William Snider’s HBIO purchases single trades or multiple transactions?

Both purchase dates reflect multiple underlying trades aggregated into weighted average prices. On each day, the Form 4 states that individual execution prices fell within specified ranges, and detailed per-trade price information is available from the insider upon request.